(Q34181598)

31 July 2017

1 reference

title

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors (English)

1 reference

31 July 2017

0 references

1 reference

Catherine Delbaldo

1

1 reference

31 July 2017

Sébastien Albert

2

1 reference

31 July 2017

Chantal Dreyer

3

1 reference

31 July 2017

Marie-Paule Sablin

4

1 reference

31 July 2017

Maria Serova

5

1 reference

31 July 2017

Eric Raymond

6

1 reference

31 July 2017

Sandrine Faivre

7

1 reference

31 July 2017

language of work or name

1 reference

28 April 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

6

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

119-124

1 reference

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

A molecular link between AKT regulation and chemotherapeutic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0177-6

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21533544

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mechanism of action of rapalogues: the antiangiogenic hypothesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21533544

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-011-0177-6

1 reference

Dimensions Publication ID

31 July 2017

1046635626

0 references

1 reference